From Science to Patients – Ideas Become Treatments at CureVac

CureVac already has several active ingredients in research and (pre-)clinical development for the treatment of cancer and for protection against infectious diseases. Until today, CureVac has tested its mRNA-based products in several clinical studies and has received clinical trial approvals in 10 European countries, Asia and the US.

Our success is tangible, inspiring us to continue on our path every day.

CureVac's Pipeline

RNA-based Cancer Therapies
Research
Pre-clinic
Phase I
Phase II
Phase III
Collaborator
NSCLC (RNActive®, Combination BI 1361849 / CV9202 with CPI)
Phase I
NSCLC (RNActive®, Combination BI 1361849 / CV9202 with CPI)
Pre-clinic
Superficial tumors (TLR-/RIG-I agonist CV8102, i.t., combination + CPI)
Phase I

CureVac’s TLR-/RIG-I agonist (CV8102) is a potent immunomodulator designed to expand the effects of immuno-oncology treatments and prophylactic vaccines for the prevention of infectious diseases.

Current Status: Phase I

Targeted tumors are melanoma, squamous cell carcinoma of skin, head and neck, adenoid cystic carcinoma.

For further information on this study please visit clinicaltrials.gov.

The press release on the start of the study can be found here.

Hepatocellular carcinoma (RNAdjuvant® / multipeptide vaccine)
Phase I
Superficial tumors (RNArt® / RNAntibody®)
Pre-clinic
Different indications (RNActive® Neoantigens in comb. with CPI)
Pre-clinic
Further undisclosed mRNA cancer therapies
Research
RNA-based Prophylactic Vaccines (RNActive®)
Research
Pre-clinic
Phase I
Phase II
Phase III
Collaborator
Rabies (CV7201, protamine formulation)
Phase I

CV7201 is an mRNA-based vaccine encoding the glycoprotein of rabies virus (RAV-G).

Current Status: Phase I

The study is designed to evaluate the safety and immunogenicity of CV7201 according to (1) dose level (2) route of injection and (3) injection schedule. Rabies-specific binding and neutralizing titers will be evaluated across different injection routes using an injection schedule of 0-7-28 and 0-28-56. Over 100 subjects have been enrolled at the University of Munich, Germany under the supervision of Dr. F.-J. von Sonnenburg.

For further information on this study please visit clinicaltrials.gov.

Rabies (CV7202, next generation formulation)
Pre-clinic
Influenza (CV7301, next generation formulation)
Pre-clinic
Diverse projects (i.e. Malaria, Influenza)
Research
RSV
Research
HIV
Research
Outbreak/ Emerging targets
Pre-clinic
RNA-based Molecular Therapies
Research
Pre-clinic
Phase I
Phase II
Phase III
Collaborator
RNAntibody®
Pre-clinic
Ornithine transcarbamylase (OTC) deficiency
Pre-clinic
Rare Disease Enzyme Replacement (undisclosed target)
Research
Gene-editing (liver)
Pre-clinic
Further undisclosed projects
Pre-clinic